查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1520532

2024-2032 年抗纤溶药物市场报告（按适应症、形式、最终用户和地区）

Antifibrinolytic Drugs Market Report by Indication, Form, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球抗纤溶药物市场规模达169亿美元。

抗纤溶药物是指用于促进血栓形成，防止动脉、静脉发生纤溶或阻塞的药物。这些药物抑制纤溶酶原的激活，从而防止纤维蛋白溶解并维持血栓稳定性。它们用于治疗出血、血管肿瘤并缓解月经出血过多。它们也用于在侵入性手术期间或之后控制出血。一些常用的抗纤维蛋白溶解药物包括氨甲环酸、抑肽酶、氨基己酸和丝氨酸蛋白酶抑制剂。它们广泛用于治疗口咽、鼻、胃肠道和子宫阴道内膜的黏膜出血。因此，它们广泛应用于医院、诊所以及创伤和门诊手术中心。

抗纤溶药物市场趋势：

道路事故、创伤和各种出血性疾病发生率的上升是推动市场成长的关键因素之一。此外，广泛采用抗纤溶药物来防止月经过多的女性以及心血管和神经外科手术期间失血，这也推动了市场的成长。抗纤维蛋白溶解药物对于防止血栓溶解和减少失血至关重要。与此一致的是，大众健康意识的提高以及对遗传性血管水肿和血友病可用治疗替代方案的认识也有助于市场的成长。各种技术进步和越来越多地使用抗纤维蛋白溶解疗法来减少骨科患者的输血是其他生长诱导因素。药厂也正在开发具有增强功效和生物吸收性的创新口服和静脉注射药物变体。其他因素，包括老年人口的增加和医疗基础设施的显着改善，预计将推动市场成长。

本报告回答的关键问题

  • 全球抗纤溶药物市场有多大？
  • 2024-2032年全球抗纤溶药物市场的预期成长率为何？
  • 推动全球抗纤溶药物市场的关键因素是什么？
  • COVID-19对全球抗纤溶药物市场有何影响？
  • 根据适应症，全球抗纤溶药物市场的细分如何？
  • 全球抗纤溶药物市场的重点区域有哪些？
  • 全球抗纤溶药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球抗纤溶药物市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依迹象

  • 妇科
    • 市场走向
    • 市场预测
  • 遗传性血管性水肿
    • 市场走向
    • 市场预测
  • 纤溶反应测试
    • 市场走向
    • 市场预测
  • 手术
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按形式

  • 口服
    • 市场走向
    • 市场预测
  • 可注射
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依最终用户

  • 医院和诊所
    • 市场走向
    • 市场预测
  • 门诊手术中心
    • 市场走向
    • 市场预测
  • 创伤中心
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 10 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 11 章：价值链分析

第 12 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 13 章：价格分析

第14章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • ACIC Pharmaceuticals Inc.
    • Akorn Inc.
    • Aurobindo Pharma Limited
    • Ferring Pharmaceuticals
    • Novartis AG
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Viatris Inc.
    • Vitruvias Therapeutics Inc.
Product Code: SR112024A5672

The global antifibrinolytic drugs market size reached US$ 16.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.2 Billion by 2032, exhibiting a growth rate (CAGR) of 3.97% during 2024-2032.

Antifibrinolytic drugs refer to the pharmaceutical medicines used for promoting the formation of blood clots to prevent fibrinolysis or blockage in arteries and veins. These drugs inhibit the activation of plasminogen, thereby preventing the lysis of fibrin and maintaining clot stability. They are used for the treatment of hemorrhages, vascular tumors and providing relief from heavy menstrual bleeding. They are also used for controlling bleeding during or after invasive surgeries. Some commonly available antifibrinolytic drugs include tranexamic acid, aprotinin, aminocaproic acid and serine protease inhibitors. They are widely used for the management of mucosal bleeding in the oropharynx, nose, gastrointestinal (GI) tract and uterine-vaginal linings. As a result, they are extensively used across hospitals, clinics and trauma and ambulatory surgical centers.

Antifibrinolytic Drugs Market Trends:

The rising incidence of road accidents, traumas and various bleeding disorders is one of the key factors driving the growth of the market. Moreover, the widespread adoption of antifibrinolytic drugs to prevent blood loss in women suffering from menorrhagia and during cardiovascular and neurosurgeries is providing a thrust to the market growth. Antifibrinolytic drugs are essential for preventing clot lysis and minimizing blood loss. In line with this, increasing health consciousness and awareness among the masses regarding the available treatment alternatives for hereditary angioedema and hemophilia are also contributing to the growth of the market. Various technological advancements and the increasing utilization of antifibrinolytic therapy to reduce transfusion in orthopedic patients are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing innovative oral and intravenous drug variants with enhanced efficacy and bio-absorbability. Other factors, including the rising geriatric population and significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antifibrinolytic drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, form and end user.

Breakup by Indication:

Gynecology

Hereditary Angioedema

Fibrinolytic Response Testing

Surgeries

Others

Breakup by Form:

Oral

Injectable

Breakup by End User:

Hospitals and Clinics

Ambulatory Surgical Centers

Trauma Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ACIC Pharmaceuticals Inc., Akorn Inc., Aurobindo Pharma Limited, Ferring Pharmaceuticals, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Viatris Inc. and Vitruvias Therapeutics Inc.

Key Questions Answered in This Report

  • 1. How big is the global antifibrinolytic drugs market?
  • 2. What is the expected growth rate of the global antifibrinolytic drugs market during 2024-2032?
  • 3. What are the key factors driving the global antifibrinolytic drugs market?
  • 4. What has been the impact of COVID-19 on the global antifibrinolytic drugs market?
  • 5. What is the breakup of the global antifibrinolytic drugs market based on the indication?
  • 6. What are the key regions in the global antifibrinolytic drugs market?
  • 7. Who are the key players/companies in the global antifibrinolytic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antifibrinolytic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Gynecology
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hereditary Angioedema
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Fibrinolytic Response Testing
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Surgeries
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Form

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Trauma Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 ACIC Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Akorn Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Aurobindo Pharma Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 Ferring Pharmaceuticals
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Takeda Pharmaceutical Company Limited
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Viatris Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Vitruvias Therapeutics Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antifibrinolytic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antifibrinolytic Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Antifibrinolytic Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Antifibrinolytic Drugs Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Antifibrinolytic Drugs Market: Breakup by Form (in %), 2023
  • Figure 6: Global: Antifibrinolytic Drugs Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Antifibrinolytic Drugs Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Antifibrinolytic Drugs (Gynecology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Antifibrinolytic Drugs (Gynecology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Antifibrinolytic Drugs (Hereditary Angioedema) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Antifibrinolytic Drugs (Fibrinolytic Response Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Antifibrinolytic Drugs (Surgeries) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Antifibrinolytic Drugs (Surgeries) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Antifibrinolytic Drugs (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Antifibrinolytic Drugs (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Antifibrinolytic Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Antifibrinolytic Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Antifibrinolytic Drugs (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Antifibrinolytic Drugs (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Antifibrinolytic Drugs (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Antifibrinolytic Drugs (Ambulatory Surgical Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Antifibrinolytic Drugs (Trauma Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Antifibrinolytic Drugs (Trauma Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Antifibrinolytic Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Antifibrinolytic Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Antifibrinolytic Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Antifibrinolytic Drugs Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Antifibrinolytic Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Antifibrinolytic Drugs Industry: SWOT Analysis
  • Figure 80: Global: Antifibrinolytic Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Antifibrinolytic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antifibrinolytic Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Form (in Million US$), 2024-2032
  • Table 4: Global: Antifibrinolytic Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Antifibrinolytic Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Antifibrinolytic Drugs Market: Competitive Structure
  • Table 7: Global: Antifibrinolytic Drugs Market: Key Players